Fluorescent imaging analysis at 24 h after exosome treatment indicated elevated levels of exosome signals in tumor-bearing hindlimbs for the BP-αCD3-αEGFR-ARC Exo-treated group relative to those of tumor-free hindlimbs of the same mice and hindlimbs without or with tumors from the mice receiving CD9-CD38/αCD3-αEGFR Exos (Fig. 5H). The gene discussed is CD9; the disease is neoplasm.